" The consistent buying pressure recently confuses me because...

" The consistent buying pressure recently confuses me because there has been no announcement to warrant it. "
Seriously ??
Check back a month ago and you will find two pretty important announcements that gave a very good signal to start buying if you like the story so far.

On Feb7
“ Clinicians have reported no safety, toxicity or tolerability issues with HER-Vaxx during the first cohort dosing of patients.
The clinical results indicate that IMU-131 induces strong immune responses in patients, with antibodies to the target cancer biomarker HER2/neu strongly evident in validated assays. Imugene Chief Scientific Officer Professor Dr. Ursula Wiedermann said, “We are pleased that there were no safety issues reported from the Cohort Review Committee. The early clinical data is also encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine’s postulated mechanism of action.”

In addition , February 12
” Novel Anti-PD-1 Mimotope Vaccine Ready for Development -Paradigm shift in treatment utilises a patient’s B cells to produce antibodies against regulatory check-point targets -Vaccine mimics check-point inhibitors – a multi billion-dollar drug class Broad platform patent filed to protect method of treatment” Check that out and do some research on what that actually means!! Clue: Imugene could quite possible gazump a$80 billion a year market with a safer, more efficient cost effective drug platform .

Have a look at all the recent deals being done in the world of immuno-oncology, you will see there are some big valuations out there. And in comparison Imugene at US$75 million market cap right now is well and truly flying under the radar. Not even in the starting blocks.

Look at the FivePrime Therapeutics deal with BMS … And note this deal was done at the Phase 1 trial stage
BMS agreed to pay Five Prime $350 million upfront and up to $1.05 billion in payments tied to development and regulatory milestone per anti-CSF1R product for oncology indications—including combinations with Opdivo and any other agent.

https://www.genengnews.com/gen-news...o-csf1r-immuno-oncology-combination/81251858/

Look at what the big Pharma companies are focusing on for their new drug pipelines and in combination with existing drugs.
Look at the consistent daily volumes we are seeing this year compared to last year.
Look at the consistent buyers / sellers ratio 5/1 for the past month….
There is so much information out there!
It leads me to believe this stock is being swallowed up by experienced investors who understand where this will end up.
As LC says, “A formidable biotech company"

As my dear old grandmother used to say “Always do your homework, it’s not that hard!”